Aysegul Arman1, Duriye Deniz Demirseren2, Tamer Takmaz1. 1. Ophthalmology Clinic, Ankara Ataturk Training and Research Hospital, Ankara 06800, Turkey. 2. Dermatology Clinic, Ankara Ataturk Training and Research Hospital, Ankara 06800, Turkey.
Abstract
AIM: To compare the effectiveness of topical cyclosporine A emulsion with that of oral doxycycline for rosacea associated ocular changes and dry eye complaints. METHODS:One hundred and ten patients with rosacea were screened. Thirty-eight patients having rosacea associated eyelid and ocular surface changes and dry eye complaints were included in the study. Patients were randomly divided into two groups: nineteen patients were given topical cyclosporine twice daily and nineteen patients were given oral doxycycline 100 mg twice daily for the first month and once daily for the following two months. Symptom and sign scores, ocular surface disease index questionnarie and tear function tests were evaluated at baseline and monthly for 3mo. Three months after results were compared with that of baseline. RESULTS:Mean values of symptom, eyelid sign and corneal/conjunctival sign scores of each treatment group at baseline and 3mo after treatments were compared and both drugs were found to be effective on rosacea associated ocular changes (P<0.001). Cyclosporine was more effective in symptomatic relief and in the treatment of eyelid signs (P=0.01). There was statistically significant increase in the mean Schirmer score with anesthesia and tear break up time scores in the cyclosporine treatment group compared to the doxycycline treatment group (P<0.05). CONCLUSION:Cyclosporine as a topical drug can be used in the treatment of rosacea associated ocular complications because it is more effective than doxycycline. In addition ocular rosacea as a chronic disease requires long term treatment and doxycycline has various side effects limiting its long term usage.
RCT Entities:
AIM: To compare the effectiveness of topical cyclosporine A emulsion with that of oral doxycycline for rosacea associated ocular changes and dry eye complaints. METHODS: One hundred and ten patients with rosacea were screened. Thirty-eight patients having rosacea associated eyelid and ocular surface changes and dry eye complaints were included in the study. Patients were randomly divided into two groups: nineteen patients were given topical cyclosporine twice daily and nineteen patients were given oral doxycycline 100 mg twice daily for the first month and once daily for the following two months. Symptom and sign scores, ocular surface disease index questionnarie and tear function tests were evaluated at baseline and monthly for 3mo. Three months after results were compared with that of baseline. RESULTS: Mean values of symptom, eyelid sign and corneal/conjunctival sign scores of each treatment group at baseline and 3mo after treatments were compared and both drugs were found to be effective on rosacea associated ocular changes (P<0.001). Cyclosporine was more effective in symptomatic relief and in the treatment of eyelid signs (P=0.01). There was statistically significant increase in the mean Schirmer score with anesthesia and tear break up time scores in the cyclosporine treatment group compared to the doxycycline treatment group (P<0.05). CONCLUSION: Cyclosporine as a topical drug can be used in the treatment of rosacea associated ocular complications because it is more effective than doxycycline. In addition ocular rosacea as a chronic disease requires long term treatment and doxycycline has various side effects limiting its long term usage.
Authors: Khayyam Durrani; Fouad R Zakka; Muna Ahmed; Mohiuddin Memon; Sana S Siddique; C Stephen Foster Journal: Surv Ophthalmol Date: 2011 Nov-Dec Impact factor: 6.048
Authors: Henry D Perry; Sima Doshi-Carnevale; Eric D Donnenfeld; Renée Solomon; Seth A Biser; Adam H Bloom Journal: Cornea Date: 2006-02 Impact factor: 2.651
Authors: Edward J Wladis; J Andrew Carlson; Matthew S Wang; Devang P Bhoiwala; Alejandro P Adam Journal: Ophthalmic Plast Reconstr Surg Date: 2013 Jul-Aug Impact factor: 1.746
Authors: Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor Journal: Drugs Date: 2020-04 Impact factor: 9.546
Authors: Gloria López-Valverde; Elena Garcia-Martin; José Manuel Larrosa-Povés; Vicente Polo-Llorens; Luis E Pablo-Júlvez Journal: Case Rep Ophthalmol Date: 2016-05-02